Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy

• DOI: 10.1097/aog.0b013e31826c32d9
• Publication Date: 2016-07-01T15:40:38Z
• Authors: Elyce Cardonick; Dzhamala Gilmandyar; Robert A. Somer
• Keywords: Adult; Dose-Response Relationship, Drug; Incidence; Pregnancy Outcome; Antineoplastic Agents; Breast Neoplasms; Gestational Age; 3. Good health; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Doxorubicin; Pregnancy; Prenatal Exposure Delayed Effects; Medical Staff, Hospital; Prevalence; Birth Weight; Humans; Female; Cyclophosphamide; Pregnancy Complications, Neoplastic; Retrospective Studies

To estimate the effect of dose-dense chemotherapy during pregnancy on maternal and neonatal outcomes.This is a retrospective cohort study in which women were identified from the international Cancer and Pregnancy Registry at Cooper Medical School at Rowan University in Camden, New Jersey. A chart analysis was completed and Fisher's exact test and independent t test were used in comparing patient outcomes.Ten women received dose-dense chemotherapy, received every 2 weeks, and 99 women received conventional chemotherapy, received with at least 3-week intervals, for breast cancer during pregnancy. Birth weight, gestational age at delivery, rate of growth restriction, congenital anomalies, and incidence of maternal and neonatal neutropenia were not statistically different between the two groups.In the small cohort of women in our registry, dose-dense chemotherapy does not appear to increase the risk of fetal or maternal complications.